Business Description
Rhythm Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US76243J1051
Compare
Compare
Traded in other countries / regions
RYTM.USA1RV.GermanyRYTM.Mexico IPO Date
2019-03-22Description
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 77.52 | |||||
| Equity-to-Asset | 0.47 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 4.16 | |||||
| Beneish M-Score | -3.44 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 1.1 | |||||
| 3-Year EPS without NRI Growth Rate | -1.7 | |||||
| 3-Year FCF Growth Rate | 5.2 | |||||
| 3-Year Book Growth Rate | -8.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 37.24 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 60.26 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 59.52 | |||||
| 9-Day RSI | 58.68 | |||||
| 14-Day RSI | 56.52 | |||||
| 6-1 Month Momentum % | 10.19 | |||||
| 12-1 Month Momentum % | 73.15 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.53 | |||||
| Quick Ratio | 6.31 | |||||
| Cash Ratio | 5.83 | |||||
| Days Inventory | 275.79 | |||||
| Days Sales Outstanding | 54.17 | |||||
| Days Payable | 187 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.3 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 88.8 | |||||
| Operating Margin % | -260.93 | |||||
| Net Margin % | -254.88 | |||||
| FCF Margin % | -120.78 | |||||
| ROE % | -164.07 | |||||
| ROA % | -79.22 | |||||
| ROIC % | -839.27 | |||||
| 3-Year ROIIC % | -187.25 | |||||
| ROC (Joel Greenblatt) % | -8729.14 | |||||
| ROCE % | -87.52 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 28.89 | |||||
| PB Ratio | 76.57 | |||||
| Price-to-Tangible-Book | 91.55 | |||||
| EV-to-EBIT | -11.78 | |||||
| EV-to-EBITDA | -11.86 | |||||
| EV-to-Revenue | 27.9 | |||||
| EV-to-Forward-Revenue | 15.28 | |||||
| EV-to-FCF | -23.08 | |||||
| Price-to-Net-Current-Asset-Value | 209.26 | |||||
| Price-to-Net-Cash | 25.85 | |||||
| Earnings Yield (Greenblatt) % | -8.49 | |||||
| FCF Yield % | -4.08 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers